Today, Feb, 13 Shineco, Inc. (NASDAQ:TYHT) with $0.45 share price, reached all time low. $0.41 price target or 8.00 % below is our PT. The all time low was reported by Barchart.com. The company has $10.27 million MC. $821,360 less could be NASDAQ:TYHT valuation at $0.41 share price.
TYHT reached $0.4489 during the last trading session after $0.0704 change.Shineco, Inc. is downtrending after having declined 75.86% since February 13, 2018. TYHT has 315,392 volume or 276.83% up from normal. TYHT underperformed the S&P500 by 75.86%.
For more Shineco, Inc. (NASDAQ:TYHT) news brought out briefly go to: Seekingalpha.com, Prnewswire.com, Prnewswire.com, Seekingalpha.com or Prnewswire.com. The titles are as follows: “U.S. Biotech/Pharma Sector Daily Observations Letter: February 14, 2018, Featuring DBV Technologies – Seeking Alpha” brought out on February 15, 2018, “Shineco, Inc. Reports Third Quarter of 2018 Financial Results – PR Newswire” on May 17, 2018, “Shineco, Inc. Announces Investment in the Integrated Financial Services Platform and Formally Enters into the Blockchain Industy – PR Newswire” with a publish date: July 09, 2018, “Conatus Pharmaceuticals among healthcare gainers; Clearside Biomedical leads the losers – Seeking Alpha” and the last “Shineco, Inc. Announces New Corporate Website Launch – PR Newswire” with publication date: May 30, 2017.
Shineco, Inc., through its subsidiaries, produces, distributes, and sells health and well-being focused plant products in China.The firm is valued at $10.27 million. It processes and distributes traditional Chinese herbal medicine products, as well as other pharmaceutical products directly to individual customers.1.36 is the P/E ratio. The firm also plants, processes, and distributes green and organic agricultural produce; and grows, cultivates, and sells yew trees that are used for the production of anti-cancer medication, as well as ornamental bonsai trees for purifying indoor air quality.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.